Cutaneous Anaplastic Large Cell Lymphoma in a Multiple Sclerosis Patient Receiving Fingolimod

Cutaneous Anaplastic Large Cell Lymphoma in a Multiple Sclerosis Patient Receiving Fingolimod Publisher Pubmed

Manouchehri N^{1, 2} ; Mirmosayyeb O^{1, 2} ; Badihian S^{1, 2} ; Shaygannejad V^{1, 3}

Show Affiliations

1. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2. Students’ Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Multiple Sclerosis and Related Disorders Published:2018

Abstract

Background Previous reports of cutaneous neoplastic lesions secondary to Fingolimod treatment among multiple sclerosis patients. Objective Reporting a case of cutaneous large cell lymphoma in a multiple sclerosis patient during Fingolimod treatment. Method Case study. Result Our patient developed CD30+ cutaneous large cell lymphoma two years after initiation of Fingolimod treatment and her symptoms regressed following the cessation of treatment. Conclusion This report indicates that cutaneous lymphoid neoplasms should be considered a possible side effect among patients receiving Fingolimod. © 2017 Elsevier B.V.

2. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)

3. Alternate Dosing of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2023)

4. Primary Cutaneous Lymphomas: A Clinical and Histological Study of 99 Cases in Isfahan, Iran, Journal of Research in Medical Sciences (2015)

5. Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients, International Journal of Preventive Medicine (2015)

6. Comparing the Efficacy of Monthly Cyclophosphamide As Monotherapy Versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis, Journal of Isfahan Medical School (2017)

7. Investigating Treatment Alternatives for Fingolimod in Patients With Multiple Sclerosis Developed Refractory Fingolimod-Related Genital Human Papilloma Virus (Hpv) Infection, Multiple Sclerosis and Related Disorders (2025)

Experts (# of related papers)

View all Related Experts

Fereshteh Ashtari (2)

Masoud Etemadifar (2)

Style	Citing Format
MLA	Manouchehri N, et al.. "Cutaneous Anaplastic Large Cell Lymphoma in a Multiple Sclerosis Patient Receiving Fingolimod." Multiple Sclerosis and Related Disorders, vol. 19, no. , 2018, pp. 121-123.
APA	Manouchehri N, Mirmosayyeb O, Badihian S, Shaygannejad V (2018). Cutaneous Anaplastic Large Cell Lymphoma in a Multiple Sclerosis Patient Receiving Fingolimod. Multiple Sclerosis and Related Disorders, 19(), 121-123.
Chicago	Manouchehri N, Mirmosayyeb O, Badihian S, Shaygannejad V. "Cutaneous Anaplastic Large Cell Lymphoma in a Multiple Sclerosis Patient Receiving Fingolimod." Multiple Sclerosis and Related Disorders 19, no. (2018): 121-123.
Harvard	Manouchehri N et al. (2018) 'Cutaneous Anaplastic Large Cell Lymphoma in a Multiple Sclerosis Patient Receiving Fingolimod', Multiple Sclerosis and Related Disorders, 19(), pp. 121-123.
Vancouver	Manouchehri N, Mirmosayyeb O, Badihian S, Shaygannejad V. Cutaneous Anaplastic Large Cell Lymphoma in a Multiple Sclerosis Patient Receiving Fingolimod. Multiple Sclerosis and Related Disorders. 2018;19():121-123.
BibTex	@article{ author = {Manouchehri N and Mirmosayyeb O and Badihian S and Shaygannejad V}, title = {Cutaneous Anaplastic Large Cell Lymphoma in a Multiple Sclerosis Patient Receiving Fingolimod}, journal = {Multiple Sclerosis and Related Disorders}, volume = {19}, number = {}, pages = {121-123}, year = {2018} }
RIS	TY - JOUR AU - Manouchehri N AU - Mirmosayyeb O AU - Badihian S AU - Shaygannejad V TI - Cutaneous Anaplastic Large Cell Lymphoma in a Multiple Sclerosis Patient Receiving Fingolimod JO - Multiple Sclerosis and Related Disorders VL - 19 IS - SP - 121 EP - 123 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract